Custom immune checkpoint polyclonal antibody discovery focuses on developing antibodies that target immune regulatory pathways. These antibodies recognize multiple epitopes, enhancing therapeutic potential compared to monoclonal antibodies. Researchers use polyclonal antibodies to study immune checkpoint mechanisms, optimize cancer immunotherapy, and improve autoimmune disease treatments. By leveraging advanced production platforms, scientists refine antibody specificity and efficacy, contributing to innovations in biomedical research and therapeutic development.